Clinical Trials Logo

Smoking, Cigarette clinical trials

View clinical trials related to Smoking, Cigarette.

Filter by:

NCT ID: NCT06296849 Recruiting - Smoking, Cigarette Clinical Trials

Dyadic Financial Incentive Treatments for Dual Smoker Couples

Start date: January 18, 2024
Phase: N/A
Study type: Interventional

Smokers partnered with other smokers (i.e., dual-smoker couples) represent ~2/3 of all smokers. Dual-smoker couples (DSCs) are less likely to try to quit smoking and more likely to relapse during a quit attempt, reducing overall smoking cessation rates and representing a high-risk clinical population. Despite their high prevalence and risk for persistent smoking, however, there are limited data on smoking cessation interventions among DSCs. Building on previous research that suggests a) financial incentive treatments (FITs) are effective at increasing quit rates and b) dyadic adaptations of FITs are feasible for implementation in DSCs, the proposed study will systematically two versions of FITs to enhance smoking cessation among DSCs. In addition to determining the efficacy of these dyadic FITs for smoking abstinence in DSCs, the investigators will consider the cost and cost effectiveness of each adaptation as well as mechanisms of change to inform future implementation research. The investigators will additionally consider secondary outcomes including abstinence during treatment and long-term abstinence maintenance after end of treatment. The investigators will address these questions in a three-group randomized controlled trial (RCT). In all conditions, individuals who have smoking partners (i.e., targets) will receive usual care (combination fast and slow acting Nicotine Replacement Therapy + quitting resources). In two conditions, participants will receive incentives for abstinence at three time points (1, 3, and 6 months post-baseline). In the SFIT condition, only the target in a couple will be offered incentives; in the DFIT condition, both target and partner will be offered incentives. Primary efficacy outcome is % point-prevalence abstinence at 6 months post-baseline among targets. Secondary outcomes are point-prevalence abstinence at 1 and 3 months during the treatment and 6 months post-treatment (12-months post-baseline), as well as partner outcomes. The investigators will evaluate possible mechanisms of change including partner support and individual and partner motivation to quit as well as evaluate the cost and relative cost of each abstainer within and across condition. These data on the efficacy, mechanisms, and costs of FITs for DSCs will inform population level implementation and promote successful quitting in this treatment refractory population.

NCT ID: NCT06190860 Recruiting - Smoking, Cigarette Clinical Trials

Platelet Rich Fibrin Treatment for the Alveolar Ridge Preservation in Smokers

Start date: May 29, 2022
Phase: N/A
Study type: Interventional

Bone healing is affected by smoking, particularly healing of extraction sockets, showing deficiencies in vertical and horizontal bone dimensions compared to the healing of non-smokers. Several approaches have been made to stimulate. Bone wound healing, including human autologous blood-derived fractions. One of these fractions is the leukocyte platelet-rich fibrin (L-PRF). L-PRF has been evidenced as potentially beneficial in promoting bone defect filling in alveolar bone and socket preservation in non-smokers. However, scarce evidence is related to this beneficial effect in smokers. This clinical trial aims to study and compare the in vivo effects of L-PRF during bone wound healing and regeneration in smokers. The main question is: Has the L-PRF a beneficial effect during alveolar ridge preservation in smokers? After consent, participants with tooth extraction indications and implant rehabilitation treatment will be enrolled. After randomization, participants will be assigned to an experimental group treated with L-PRF plugs and membranes or a control group (physiological healing). Participants will receive two interventions: - First intervention: Tooth extraction, intraoral scan, and Cone Beam Computed Tomography in the treated zone. - Second intervention (4 months after first intervention): intraoral scan and Cone Beam Computed Tomography in the treated zone

NCT ID: NCT05973981 Recruiting - Smoking, Cigarette Clinical Trials

The Impact of Standardized Tobacco Product Packaging on Young Adults in the Retail Environment

Start date: May 4, 2022
Phase: N/A
Study type: Interventional

The overall aim of this research is to experimentally evaluate the extent to which partially standardizing the color of tobacco packaging influences tobacco use intentions among young adults who have varying levels of tobacco use experience.

NCT ID: NCT05962801 Recruiting - Periodontitis Clinical Trials

Use of Dual-light Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers

Start date: January 23, 2023
Phase: N/A
Study type: Interventional

The goal of this controlled clinical trial is to investigate the impact of regular home use of Lumoral device as an adjunct treatment compared to non-surgical periodontitis treatment (NSPT) alone on biofilm removal and host response in Stage III and Grade C smoking periodontitis patients at 6 months.The main question aims to answer is: • Does regular use of dual-light photodynamic therapy benefit NSPT in Stage III and Grade C smoking periodontitis patients? 30 participants will be asked to use Lumoral device every night before performing oral hygiene for 10 minutes, while the other 30 patients will be asked to perform only oral hygiene. Both of these groups will receive NSPT and will be followed for 6 months from baseline.

NCT ID: NCT05736250 Recruiting - Smoking, Cigarette Clinical Trials

Establishment of a Method for Extraction and Quantification of Gingival Tissue Nicotine y

Start date: January 14, 2022
Phase:
Study type: Observational

establishment of a method for extraction and quantification of gingival tissue nicotine in relation to conventional tobacco biomarkers: a pilot study

NCT ID: NCT05683821 Enrolling by invitation - Smoking Cessation Clinical Trials

BREATHE 2 Clinic Stop-Smoking Treatment Outreach Study

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

The purpose of this research study is to see if offering adult primary care patients who smoke combustible cigarettes more frequent outreach, more choices about how they receive that outreach, and more smoking treatment options will increase the use of smoking treatments and help more people quit smoking, when compared against a standard outreach approach. Only patients at participating adult primary care clinics will be eligible for the study. Five clinic sites will be randomized to an enhanced outreach approach, while another 5 will be randomly assigned to standard smoking treatment outreach. Eligible patients at these clinics will be in this study for up to 18 months.

NCT ID: NCT05660525 Recruiting - Smoking Cessation Clinical Trials

Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia

Start date: March 6, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness and implementation of a pharmacist-delivered MTM (medication therapy management) approach, called QuitAid, to quitting cigarette smoking in rural Appalachia. The main questions it aims to answer are: - Is QuitAid, alone or combined with other quitting tobacco treatments, effective? - What makes QuitAid easy or hard to carry out? Is it cost effective? Is it easy to maintain? Treatment: All participants will be given at least 4 weeks of the nicotine patch. Some participants will be randomized (like the flip of a coin) to receive additional treatments (listed below). These groups will be compared to each other to see which combination works best to help them quit smoking. - Smokefree TXT - a texting program that helps people quit smoking - Tobacco quitline - 4 phone sessions to help people quit smoking - 8 weeks of NRT (nicotine replacement therapy in the form of nicotine patches or nicotine patches and lozenge) medication instead of 4 weeks - QuitAid - An MTM program given by the patient's pharmacist. This is a quitting smoking coaching program - Nicotine patch AND nicotine lozenge instead of just nicotine patches

NCT ID: NCT05484505 Not yet recruiting - Smoking Cessation Clinical Trials

Preloaded Combination Nicotine Replacement Therapy on Smoking Cessation of Adult Population in Kazakhstan

Start date: July 1, 2023
Phase: Early Phase 1
Study type: Interventional

Randomized, controlled, two-armed, single-blinded, superiority trial with 1:1 allocation ratio Nicotine Replacement Therapy(NRT)

NCT ID: NCT05473585 Completed - Smoking Clinical Trials

Impact of New Standards for Tobacco Products Among Dual E-Cigarette/Combusted Cigarette Users - Project 2

Start date: October 12, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate how limiting the nicotine content in regular cigarettes affects choices for regular cigarette and e-cigarette products. Eligible participants will be of legal age to purchase tobacco products and regularly use both e-cigarettes and regular cigarettes.

NCT ID: NCT05426460 Active, not recruiting - Smoking, Cigarette Clinical Trials

AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior

Start date: April 29, 2022
Phase: N/A
Study type: Interventional

Smokers are highly reactive to smoking-related stimuli and report that this cue reactivity (CR) is a major obstacle to quitting. To date, no pharmacologic methods attenuate CR, and attempts to diminish it with traditional cue exposure treatment (CET) have not proven effective. The proposed study will test a highly novel cue-based smoking treatment adjunct combining an Approach/Avoidance Task (AAT) with brain stimulation via tDCS applied to the dorsolateral prefrontal cortex (dlPFC) during personalized multi-cue exposure; the goal of which is to discover an effective means of reducing cue reactivity and daily smoking, and increasing intent and confidence to quit, among high treatment-interest smokers.